Business Wire

Mori Building Unveils Massive Urban Regeneration Project in Central Tokyo

Share

Mori Building Co., Ltd., a leading urban landscape developer, has begun construction on its “Toranomon-Azabudai District Category 1 Urban Redevelopment Project,” a massive urban regeneration project aimed at revitalizing a large area of central Tokyo. A groundbreaking ceremony was held on August 5 and project completion is scheduled for the end of March 2023.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190821005445/en/

Image of Office Lobby (Graphic: Business Wire)

Image of Office Lobby (Graphic: Business Wire)

The core concept of the Toranomon-Azabudai Project is that of a “Modern Urban Village,” a unique neighborhood that will combine the sophistication of a megalopolis with the intimacy of a small village in the heart of Tokyo. It will cover an area of approximately 8.1 hectares, similar to that of New York’s Rockefeller Center, and will feature extensive greenery totaling 24,000 m2 including a 6,000 m2 central square. Total floor area will be 860,400 m2, including 213,900 m2 of office space and about 1,400 residential units. Some 20,000 office workers and 3,500 residents will work and live there, and 25-30 million people per year are expected to visit this totally new city-within-a-city.

Its physical structures will incorporate cutting-edge seismic designs and technologies, with dedicated power stations supplying electricity to the whole neighborhood. The project is designed to provide a safe city that will allow people to carry on living and working even in the event of a major disaster on the scale of the Great East Japan Earthquake. Mori Building’s unsurpassed safety and security measures are designed to create cities to escape to, rather than flee from.

Green & Wellness for enhanced lifestyles

The Toranomon-Azabudai Project will create a “unique people-centered space” by blending diverse elements and creating a world of its own. The project will seamlessly weave offices, residences, a hotel, an international school, retail shops, restaurants and cultural facilities into the fabric of everyday life, encompassing work, learning, recreation, interaction and relaxation. Built around innovative features that will include a village-like plaza surrounded by greenery, the project will create an urban space where people achieve harmony with nature as well as connecting with and inspiring each other with creativity. Far more than a mere grouping of buildings, the project will realize an integrated social ecosystem based on a people-centered approach to planning.
The core theme of the project is the huge 6,000 m2 central square offering “Green & Wellness” that will allow people from its diverse communities to gather and meet. A significant proportion of the site, including spaces on top of podium buildings, will be covered with greenery to take advantage of the stepped architecture. There will be more than two hectares of green space, including the central square, creating a seamless urban oasis filled with trees, flowers and waterscapes.

100% of the electricity supplied to the entire neighborhood will be from renewable sources, which will meet the targets stipulated in the RE100 international environmental initiative led by the UK’s Climate Group. The mental and physical wellbeing of people living and working in the area will be supported with wellness programs involving medical facilities, sports facilities, a food market, restaurants and the environment of the central square. Mori Building will apply for project certification under the WELL Building Standard™ of the International WELL Building Institute™.

A city where various aspects of people's lives will be connected seamlessly

The Toranomon-Azabudai Project will result in an urban environment where various aspects of people’s lives— working, living, relaxing, getting together, learning, playing—will be seamlessly connected. Rather than designing the city around facilities such as offices, residences and hotels, Mori Building is approaching this development from the perspective of human activity by removing the barriers between facilities. Here, various facilities will interact and collaborate, offering people the opportunity of totally new lifestyles; a place where people can spend their life in harmony with nature, where they will meet and live in a community, and where they can live creative and stimulating lives. The entire city, full of greenery, will become a place of learning, a workplace, a home, and a playground.

Leading global innovators help to implement a “Modern Urban Village” concept

The world's top creators were assembled to realize the design of this unique “Modern Urban Village,” with Mori Building playing a pivotal role in the project organization. Public realm and lower level architecture were created by Heatherwick Studio from the UK, led by Thomas Heatherwick, the designer and creator of the London 2012 Olympic Cauldron. The three skyscrapers were designed by Pelli Clarke Pelli Architects from the USA under the direction of the late César Pelli and Fred Clarke. The retail space was designed by Sou Fujimoto Architects of Japan, led by Sou Fujimoto. Other noted experts from around the world also participated.

Main participating architects, creators and designers

• Thomas Heatherwick,

Founder of Heatherwick Studio

• César Pelli (dec.)

Pelli Clarke Pelli Architects

• Fred Clarke

Pelli Clarke Pelli Architects

• Sou Fujimoto,

Sou Fujimoto Architects (Japan)

• Glenn Pushelberg and George Yabu,

Yabu Pushelberg (Canada)

• Marco Costanzi,

Marco Costanzi Architects (Italy)

• Soo K. Chan, SCDA (Singapore)

Tyler Brûlé, Winkreative (UK)

Connecting the “Hills” and creating a new cultural and economic heart of Tokyo

Mori Building’s strategic area, which incorporates the district encompassed by the Toranomon-Azabudai Project, straddles the center of Tokyo’s Minato City. The area has long had an international feel to it; many foreign-minded companies gravitate here, and it hosts a large number of foreign residents. Rich in international flavors, diversity and culture, this area has extremely high potential to become a new international hub of Tokyo.

The new project site is adjacent to Mori Building’s ARK Hills complex at the midpoint between Roppongi Hills, the “Cultural Heart of Tokyo”, and Toranomon Hills, the “Global Business Hub”. These existing Hills projects will be linked by the Toranomon-Azabudai Project; this will enhance the evolution of the entire area, creating a new international urban focal point as well as a new cultural and economic hub in the heart of Tokyo.

Project overview

Project name:

Toranomon-Azabudai District Category 1 Urban Redevelopment Project

Project executor:

Toranomon-Azabudai District Urban Redevelopment Association

Site area:

Approx. 8.1 hectares

Ground area:

Approx. 63,900 square meters

Total floor area:

Approx. 860,400 square meters

Buildings:

Residences (1,400 units), offices (approx. 213,900 m2), retail facilities (approx. 150 shops), hotel (approx. 120 rooms), international school (approx. 14,000 m2), central square (approx. 6,000 m2), cultural facilities (approximately 9,000 m2)

Greenery:

Approx. 2.4 hectares

Parking:

Approx. 1,880 spaces

Project cost:

Approx. JPY 580 billion

Members:

285 rights holders (as of March, 2019)

Construction start:

August 5, 2019

Planned completion:

March 31, 2023

 

If you wish to edit the images, or you would like materials not included in these downloads (e.g. designers’ photographs) please contact Weber Shandwick Japan by email to moribldg@webershandwick.com.

Download link:(by Sep 23rd, 2019)

https://bit.ly/2TKtmUu

Password:mori20xx

About Mori Building

Mori Building is an innovative urban developer based in Tokyo. The company is committed to maximizing the magnetic power of cities by creating and nurturing safe, sustainable and cosmopolitan urban centers based on its unique Vertical Garden City concept of high-rise centers for business, education, leisure and residences. The concept has been applied in the company’s many leading-edge projects, including ARK Hills, Roppongi Hills and Toranomon Hills in Tokyo and the Shanghai World Financial Center. Mori Building is also engaged in real estate leasing, project management and consultation. Please visit www.mori.co.jp/en

Contact information

International Media Inquiries
Public Relations, Mori Building Co., Ltd.
Tel +81 (0)3-6406-6606
Fax +81 (0)3-6406-9306
E-mail koho@mori.co.jp

Weber Shandwick Japan
Kaya Tanabe (phone: +81 (0)90 7726 7027), Reina Matsushita (+81 (0)80 2375 0295),
Mayuko Harada (+81 (0)90 9006 4968) or Masashi Nonaka (+81 (0)80 1037 7879)
E-mail moribldg@webershandwick.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced the results of the Phase 2 Pevonedistat-2001 trial will be presented during oral sessions at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the virtual 25th European Hematology Association (EHA) Annual Meeting. The study evaluated pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including higher-risk myelodysplastic syndromes (HR-MDS). These results show that the combination of pevonedistat and azacitidine is a highly active, promising therapeutic approach and suggest benefit in the HR-MDS subgroup across multiple clinically meaningful endpoints, including overall survival (OS), event-free survival (EFS), complete remission (CR) and transfusion independence, with a safety profile similar to azacitidine alone. The Pevonedistat-2001 trial was designed as a proof-of-concept study in patients with HR-MDS, higher-risk chronic myelomonocytic leuke

LetsGetChecked Debuts FDA EUA-Authorized At-Home Coronavirus (COVID-19) Sure-track Test29.5.2020 14:57:00 EESTPress release

LetsGetChecked, the leading direct-to-consumer at-home health testing and insights company, announces today the authorization of the new Coronavirus (COVID-19) Sure-track Test for at-home consumer use by the U.S. Food and Drug Administration under an EUA. The new test is authorized to serve at-risk individuals with a proprietary at-home PCR nasal swab test that delivers accurate and definitive results within 24 hours. Offering an end-to-end model, LetsGetChecked’s new Sure-track Test introduces the most complete FDA EUA-authorized Coronavirus at-home testing solution. The at-home Coronavirus (COVID-19) test incorporates a nasal swab and PCR lab analysis, offering convenient and secure results in 24 hours. Unlike serology tests that detect the presence of antibodies, the at-home COVID-19 test determines the presence or absence of SARS-CoV-2 viral RNA. LetsGetChecked’s Sure-track Test is the only FDA EUA-authorized at-home Coronavirus (COVID-19) test that owns all aspects of the testing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom